December 11, 2017
The combination of selinexor and sorafenib appears to be safe with clinical activity and apoptosis induction in patients with relapsed and/or refractory FLT3-mutated acute myeloid leukemia […]
December 5, 2017
A new study has found that inhibiting the METTL3 gene destroys human and mouse acute myeloid leukemia (AML) cells without harming non-leukemic blood cells
November 13, 2017
Treatment with first-line bosutinib resulted in improved outcomes for patients with chronic-phase chronic myeloid leukemia (CML) compared with treatment with imatinib, according to results of the […]
November 9, 2017
Clinicians now have a new first-line therapy that may significantly improve care for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC). On […]
September 13, 2017
When oncologist Dr. Carl June heard the Food and Drug Administration’s decision to bring the first gene therapy to market in the US, he pinched himself, […]
August 18, 2017
The US Food and Drug Administration (FDA) has approved inotuzumab ozogamicin (Besponsa) for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in […]
July 6, 2017
Nivolumab was associated with durable objective response rates (ORRs) in adults with relapsed or refractory classical Hodgkin lymphoma after autologous stem cell transplantation (ASCT), according to […]
June 28, 2017
Clinicians may soon have a new tool to aid patients with refractory acute myeloid leukemia (AML). Researchers at the Perelman School of Medicine at the University […]
June 20, 2016
The American Society of Clinical Oncology’s annual meeting, one of the most important cancer conferences of the year, concluded June 7th. This year’s theme was ‘collective […]
February 5, 2016
The American Society of Hematology (ASH), the premier event for scientific exchange in the field of hematology, recently concluded its annual meeting in Orlando, Florida. Oral […]
July 7, 2015
The annual American Society of Clinical Oncology (ASCO) meeting was held last week in Chicago, bringing together thousands of oncology professionals from around the world to […]
February 19, 2015
The tyrosine kinase inhibitor famitinib was associated with a significant improvement in progression-free survival among patients with advanced or metastatic colorectal cancer, according to the results […]
February 19, 2015
Patients with hepatocellular carcinoma (HCC) may derive greater benefit from treatment with second-line ramucirumab if their baseline alpha-fetoprotein (AFP) levels are greater than 400 ng/mL, according […]
February 19, 2015
Patients with rectal cancer who completed neoadjuvant therapy with a clinical complete response but did not undergo rectal resection had similar 4-year survival rates as patients […]
February 19, 2015
Newly diagnosed metastatic colorectal cancer patients with higher vitamin D levels had better outcomes after treatment with a combination of chemotherapy and targeted therapy. The results […]
February 19, 2015
The addition of the novel agent MM-398 to second-line 5-FU/leucovorin extended survival in patients with metastatic pancreatic cancer, according to an expanded analysis of the phase […]
February 19, 2015
Twice as many patients with metastatic colorectal cancer remained alive after 5 years with a four-drug chemotherapy regimen plus bevacizumab (Avastin) versus three drugs and the […]
February 19, 2015
The 2015 ASCO Gastrointestinal Cancers Symposium, held last month in San Francisco, brought together oncology professionals to highlight the latest research and science in cancers of […]
December 12, 2014
SAR650984 (SAR) is another anti-CD38 antibody that has shown single-agent activity in Phase I testing among heavily pre-treated myeloma patients. In this Phase Ib trial, researchers […]
December 12, 2014
The recently approved targeted treatment carfilzomib has been shown to help slow or halt the spread of cancer by targeting the mechanisms that control excess proteins […]
December 12, 2014
The AETHERA Trial: Results of a Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Brentuximab Vedotin in the Treatment of Patients at Risk of Progression Following Autologous […]
December 12, 2014
New treatment combinations and targeted therapies for lymphoma and multiple myeloma are improving outcomes for vulnerable patient populations with hard-to-treat disease, according to studies presented at […]
December 12, 2014
Novel treatments that harness the body’s own immune cells to attack cancer cells demonstrate safe and durable responses in patients with relapsed and treatment-resistant blood cancers, […]
December 12, 2014
Targeted Therapy Effective in Elderly Patients with Philadelphia-Positive Acute Lymphocytic Leukemia
While rates of remission among elderly patients with leukemia continue to improve, the outlook remains poor among those with a disease subtype present in nearly one-third […]
December 12, 2014
Recognizing that leukemia cannot be conquered with a “one-size-fits-all” approach, researchers are pursuing novel targeted therapies and combinations of existing treatment regimens with new agents for […]
December 12, 2014
The American Society of Hematology (ASH) is the world’s largest professional society of hematologists dedicated to furthering the understanding, treatment, and prevention of disorders affecting the […]
October 7, 2014
Cancer researchers have been almost giddy in the last couple of years about the potential of drugs like Keytruda, which seem to solve a century-old mystery […]
October 7, 2014
Could you discuss the KEYNOTE study results and the approval of pembrolizumab? Pembrolizumab was approved because it is active for the treatment of metastatic melanoma and […]
September 26, 2014
Last week, the FDA approved pembrolizumab (Keytruda) for the treatment of patients with advanced or unresectable melanoma following progression on prior therapies. In the pivotal KEYNOTE-001 […]
August 15, 2014
MHOA Monthly Newsletter No.1 Positivity in Adversity “Strength does not come from physical capacity. It comes from indomitable will.” -Mahatma Ghandi
August 1, 2014
[mc_carousel id=”carousel” carousel_images=”2770,2771,2772,2750,2773″ features_images_loop=”1″ lightbox_icon_color=”blue_light” autoplay=”0″ pause_on_hover=”1″ scroll=”1″ effect=”scroll” easing=”swing” duration=”500″ top_margin=”page_margin_top_section” el_position=”first last”] Thank You For Your Interest In Clinical Trials at MHOA Currently Enrolling […]
August 1, 2014
“I love the fact that today, with all the advances in diagnostics, drugs, and personalized cancer treatments, working with cancer patients is an exciting and optimistic […]
August 1, 2014
Brain Cancer New tumor-targeting agents (APC) able to seek out and find solid tumors, even illuminating brain cancer stem cells that resist current treatments Science Daily […]